Results 41 to 50 of about 7,241 (205)

Controversies in the treatment of idiopathic membranous nephropathy [PDF]

Nature Reviews Nephrology, 2009
Optimum treatment of idiopathic membranous nephropathy is both controversial and challenging. The most extensively studied and frequently used immunosuppressive regimens for this disease comprise alkylating agents plus corticosteroids or ciclosporin. All of these treatment options have inherent problems: they are not effective in all patients, partial ...
Meryl, Waldman, Howard A, Austin
openaire   +2 more sources

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

Kidney International Reports
Introduction: Rituximab is a first-line treatment for primary membranous nephropathy (pMN), with proven efficacy and safety. The use of monoclonal antibodies such as rituximab can lead to the formation of antidrug antibodies that may interfere with the ...
Marco Allinovi, Maxime Teisseyre, Matteo Accinno, Cecilia Finocchi, Vincent L.M. Esnault, Marion Cremoni, Tommaso Mazzierli, Daniela Lazzarini, Micaela Anna Casiraghi, Céline Fernandez, Kévin Zorzi, Vesna Brglez, Lorenzo Cosmi, Andrea Matucci, Leonardo Caroti, Giulia Antognoli, Calogero Lino Cirami, Alessandra Vultaggio, Barbara Seitz-Polski   +18 more
doaj   +1 more source

Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy – a retrospective cohort study

Romanian Journal of Internal Medicine, 2019
Introduction. Circulating autoantibodies against phospholipase A2 receptor (anti-PLA2R) are recognized as key elements in the pathogenesis of idiopathic membranous nephropathy.
Provatopoulou Simella, Kalavrizioti Dimitra, Stangou Maria, Kouri Maria-Nikoleta, Kalliakmani Pantellitsa, Papasotiriou Marios, Papachristou Evangelos, Goumenos Dimitrios S., Papagianni Aikaterini   +8 more
doaj   +1 more source

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies

Kidney International Reports
Introduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur.
Maxime Teisseyre, Marco Allinovi, Vincent Audard, Marion Cremoni, Giulia Belvederi, Alexandre Karamé, Matteo Accinno, Julien Duquesne, Vinod Sharma, Céline Fernandez, Kévin Zorzi, Mounir El Maï, Vesna Brglez, Sylvia Benzaken, Vincent L.M. Esnault, Alessandra Vultaggio, Harbir Singh Kohli, Raja Ramachandran, Calogero Lino Cirami, Barbara Seitz-Polski   +19 more
doaj   +1 more source

Idiopathic Membranous Nephropathy: An Autoimmune Disease [PDF]

Seminars in Nephrology, 2011
For more than 50 years researchers have debated the evidence for an autoimmune basis of human idiopathic membranous nephritis (MN). Work published in the past 2 years has substantially strengthened the belief that MN is indeed an autoimmune disease of the kidney. Autoantibodies of the IgG4 subclass to at least three podocyte membrane proteins including
Sudesh P, Makker, Alfonso, Tramontano
openaire   +2 more sources

Circulating Antibodies against Thrombospondin Type-I Domain -Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy

, 2017
Background and objectives Thrombospondin type-I domain containing 7A (THSD7A) was recently identified as the target antigen in about 10% of patients with M-type phospholipase A2 receptor (PLA2R) negative membranous nephropathy in European and North ...
Liu, Gang, Probst, Christian, Cui, Zhao, Pierre Ronco, Wang, Xin, Ronco, Pierre, Hanna Debiec, Fang Wang, Zhao Cui, Xin Wang, Ming-hui Zhao, Lu, Jie, Qu, Zhen, Jia Wang, Debiec, Hanna, Meng, Li-qiang, Jie Lu, Li-qiang Meng, Zhang, Yi-miao, Zhen Qu, Christian Probst, Yi-miao Zhang, Wang, Jia, Wang, Fang, Gang Liu, Zhao, Ming-hui, Cheng, Xu-yang, Xu-yang Cheng   +27 more
core   +1 more source

Immunosuppression and outcome in idiopathic membranous nephropathy [PDF]

QJM, 1998
From 1986 to 1996, 53 patients with idiopathic membranous nephropathy (IMN) presented to the Glasgow Royal Infirmary renal unit: 19 (36%) were treated because of progressive disease. We compared outcomes of treated and untreated patients with 37 historical and untreated controls.
C M, Stirling, K, Simpson, J M, Boulton-Jones   +2 more
openaire   +2 more sources

Transplant Outcomes in Patients with Idiopathic Membranous Nephropathy [PDF]

, 2020
Background. The natural history of idiopathic membranous nephropathy and recurrent disease in transplants is variable. We performed a retrospective cohort study of renal transplant recipients with a primary diagnosis of idiopathic membranous nephropathy.
Patrick O'kelly, Claire Kennedy, Peter J Conlon, Carol Traynor, Anthony Dorman   +4 more
core  

DataSheet_1_Construction of a Nomogram Discriminating Malignancy-Associated Membranous Nephropathy From Idiopathic Membranous Nephropathy: A Retrospective Study.csv

, 2022
BackgroundBased on the etiology, membranous nephropathy (MN) can be categorized into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy. Malignancy-associated membranous nephropathy (MMN) is a common type of secondary MN.
Ting Wang (16292), Wei Yu (43094), Feng Wu (12185), Yiding Zhang (1428880), Jin Shang (704634), Zhanzheng Zhao (3328092)   +5 more
core   +1 more source

Value of M-type phospholipase A2 receptor in clinical diagnosis and treatment of membranous nephropathy:recent advances and current controversies

Linchuang shenzangbing zazhi, 2021
The sensitivity of serum anti-M-type phospholipase A2 receptor antibodies（anti-PLA2 R Abs）is 70%～80% in idiopathic membranous nephropathy and the specificity over 95%.This article reviewed the latest research advances on the pathogenesis,diagnosis ...
Wang Hui, Jiang Man, Zhang Di, Wang Yu-qin   +3 more
doaj